Patent application number | Description | Published |
20110059082 | AGENT FOR TREATING DISEASE - The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg. | 03-10-2011 |
20110059083 | AGENT FOR TREATING DISEASE - The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days. | 03-10-2011 |
20110059084 | AGENT FOR TREATING DISEASE - The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg. | 03-10-2011 |
20110123554 | USES OF IMMUNOCONJUGATES TARGETING CD138 - Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination. | 05-26-2011 |
20110229465 | COMPOSITION FOR TREATING DISEASE - The present invention provides pharmaceutical compositions and kits comprising an agent capable of activating CD4+CD25+ regulatory T cells and methotrexate, and methods of treatment and medical uses utilising the same. | 09-22-2011 |